Search
Close this search box.

Scott Winder joins RNA to expand its Life Science Tax and Financial Reporting Valuation Group

Client Success: Healthcare Transaction Support to Assess Value from Different Perspectives

By Jeff Williamson THE SITUATION: A healthcare company with a portfolio of products in development for treating cardiac conditions was fielding investor interest for a potential acquisition. The company wanted to weigh the relative merits of raising additional equity financing versus exploring multiple M&A offers, as these initial discussions indicated a price range that did […]

Client Success: Navigating Strategic Investment in Healthcare Technology

THE PROBLEM: A healthcare technology company that sells its FDA 510(k) approved device and supporting dashboarding and analytic tools to hospitals was in the midst of a capital raising effort involving a one-on-one negotiation with an existing strategic partner. The company received from the strategic partner a “low-ball” valuation. The company’s management team and board […]

Why Valuation Matters in Early-Stage Life Sciences

“Value”, the outcome of a thorough valuation analysis, is ultimately what parties agree to. Sometimes this seems a rational outcome, other times an irrational one. The reality is that a life sciences or healthcare technology company’s valuation often results from the ability or inability to create an effective bidding process and to persuade/anchor a strategic […]

Client Success: Derivatives Valuation for pre-IPO Biotechnology Company

THE PROBLEM: A development stage biotechnology company (considering an IPO in the near future) entered into a series of financings which required the valuation of components of the financings deemed to be a derivative for financial reporting purposes. THE SOLUTION: RNA worked with the company and their Big 4 auditor to develop a Monte Carlo […]

Client Success: Portfolio Valuation for LPs of $1B + Healthcare-Focused PE Firm

THE PROBLEM: Two of the largest pension funds in the world required an independent valuation assessment of the portfolio of a multi-billion dollar life science/ healthcare private equity fund. THE SOLUTION: Robust research, forecasting, modeling, comp analysis and valuation analytics to determine reasonableness of value indications. “We love working with you.  You actually know what […]

Sign Up for Periodic Updates

Enter your email address below to receive updates from RNA Advisors.